Parkinson's Cell Therapy! Bayer DA01 And Cistanche

ali.ma@wecistanche.com

BlueRock Therapeutics, a wholly-owned subsidiary of Bayer, recently announced that it has collaborated with University Health Network (UHN) to evaluate the first open-label Phase 1 study (Ph1) of DA01 in patients with advanced Parkinson's disease (PD). patients were treated with medication.

DA01, a pluripotent stem cell-derived dopaminergic neuron, is a first-of-its-kind cell therapy with the potential to regenerate lost function and potentially improve and reverse Parkinson's disease. Currently, DA01 is being clinically evaluated in a subset of patients with advanced Parkinson's disease who are no longer fully effective with conventional drug therapy. DA01 is surgically implanted into the patient's brain, where it integrates into the brain and restores lost physiological function. This treatment, if successful, could lead to major advances in Parkinson's disease.

Cistanche protect the neurons and treat Parkinson's disease (PD)

The primary objective of the Phase 1 trial is to evaluate the safety and tolerability of DA01 cell transplantation one year after transplantation. Secondary goals were to assess evidence of transplanted cell survival and motility effects at 1 and 2 years post-transplant, to assess continued safety and tolerability during the 2-year period, and to assess the feasibility of transplantation.

Click to maca root ginseng cistanche sea horse for Parkinson's disease

Parkinson's disease (PD) is a progressive neurodegenerative disease caused by damage to nerve cells in the brain, resulting in a drop in dopamine levels. The exacerbation of motor and non-motor symptoms is caused by the loss of dopamine-producing neurons. It is estimated that patients have lost 60-80% of their dopaminergic neurons at the time of diagnosis.

Parkinson's disease usually begins with a tremor in one hand. Other symptoms include stiffness, cramping, and slow movement (bradykinesia). According to the Parkinson's Foundation, more than 10 million people around the world suffer from Parkinson's disease, and one million of them live in the United States.

BlueRock Therapeutics is a leading engineered cell therapy company on a mission to create true cellular medicines to reverse devastating diseases, with a vision to improve the human condition. The company's Cell + Gene platform harnesses the power of cells to develop innovative therapies for neurology, cardiology, immunology, and ophthalmology indications.

Cistanche extract for Parkinson's disease (PD)

BlueRock Therapeutics' cell differentiation technology recreates the developmental biology of cells to generate truly believable cells, some of which are engineered for additional therapeutic functions. Using these cell therapies to replace damaged or degenerated tissue has the potential to restore lost function. Founded in 2016 by Versant Ventures and Bayer, BlueRock Therapeutics was capitalized by Bayer and Versant Ventures in one of the largest Series A financings in biotech history. The company was fully acquired by Bayer in 2019.

Cistanche tablets for Parkinson's disease (PD)

Note： The traditional Chinese medicinal herb cistanche (also known as the "dragon herb" and "desert ginseng"), grows only in the arid and warm deserts. As one of the nine immortal herbs, Cistanche (cistanche tubulosa/cistanche deserticola/desertliving cistanche/cistanche salsa)contents with rich effective ingredients such as echinacoside, acteoside, total phenylethanoid glycosides, flavonoids, polysaccharides, etc. these effective ingredients made cistanche a precious nourishing herb and food material for people's immunity, internal organs, and brain cells and neurons, etc. The modern pharmacological studies have confirmed the following effects of cistanche(benefits of cistanche): improve immunity; improve sexual function and kidney function; anti-fatigue; anti-aging; improve memory; anti-Parkinson's disease; anti-Alzheimer's disease; antioxidation; ease-constipation; anti-inflammatory; promote bone growth, whitening skin; protect liver; etc.